Fig. 3

Treatment patterns overall and stratified by year of first-line therapy initiation. The graph shows the numbers of patients who received the treatments indicated in the legend. The table shows the numbers and percentages of patients who received each treatment regimen, along with proportions of patients receiving different types of anti–PD-1/PD-L1 monotherapy, pembrolizumab plus platinum-based chemotherapy, and nivolumab plus ipilimumab, which are shown below the relevant regimen category. During 2020, the COVID-19 pandemic may have impacted routine clinical care. Percentages reported for subcategories are proportions in the respective category, not the whole. CT, chemotherapy; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1